MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.7 EUR | 0.00% |
|
-0.37% | +99.12% |
| Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
| Apr. 11 | Trending : Novartis Begins Tender Offer for MorphoSys Shares | DJ |
Chart calendar MorphoSys AG
c9d9c7f5b60a5d416.0BZ18r7E8RhrehOg98BUXB_gebFjyl6NGupIM4J5_X0.oUYCiPaDtVxbT3DPkpdgCS-TOogIhAu_La8rYMoQqhq0ciKh05OESz0rQg~aa1e2312597232b8df4d25307c386c4b
Upcoming events on MorphoSys AG
Past events on MorphoSys AG
| 2024-03-14 08:00 am | Q4 2023 Earnings Call |
| 2024-03-13 04:01 pm | Q4 2023 Earnings Release |
| 2024-02-06 08:00 am | Acquisition of MorphoSys AG by Novartis AG Call |
| 2024-01-10 06:00 pm | JPMorgan Healthcare Conference |
| 2023-12-11 10:00 am | American Society of Hematology Meeting |
| 2023-12-10 09:00 pm | American Society of Hematology Meeting |
| 2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No:3195 |
| 2023-12-10 09:00 pm | American Society of Hematology Meeting - Abstract No:2813 |
| 2023-12-10 08:15 pm | American Society of Hematology Meeting - Abstract Number #628 |
| 2023-12-10 07:30 pm | American Society of Hematology Meeting - Abstract No:628 |
| 2023-12-09 08:30 pm | American Society of Hematology Meeting - Abstract No:2415 |
| 2023-12-09 05:00 pm | American Society of Hematology Meeting - Abstract No:265 |
| 2023-12-05 12:30 pm | JMP Securities Hematology and Oncology Summit |
| 2023-11-21 08:00 am | MANIFEST 2 Phase III Results Call |
| 2023-11-16 08:00 am | Q3 2023 Earnings Call |
| 2023-11-15 04:01 pm | Q3 2023 Earnings Release |
| 2023-11-15 07:30 am | Jefferies London Healthcare Conference |
| 2023-11-07 | Truist Securities Healthcare Conference |
| 2023-09-13 02:55 pm | Morgan Stanley Global Healthcare Conference |
| 2023-09-07 01:30 pm | Wells Fargo Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 71,8 71,5 0.3% | 328 327 0.23% | 180 173 3.64% | 278 249 11.77% | 238 240 -0.63% | 252 |
|
EBITDA Million EUR | Released Forecast Spread | -102 -97,4 -4.36% | 35,7 37,7 -5.31% | -268 -282 5.09% | -210 -242 13.27% | -242 -250 3.07% | -169 |
|
EBIT Million EUR | Released Forecast Spread | -108 -98,9 -9.11% | 27,4 37,0 -25.96% | -278 -290 4.15% | -221 -253 12.92% | -253 -258 1.96% | -180 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -107 -97,6 -9.13% | 22,5 21,8 3.28% | -591 -267 -121.79% | -320 -480 33.43% | -191 -258 26.08% | -148 |
|
Net income Million EUR | Released Forecast Spread | -103 -96,9 -6.28% | 97,9 25,4 285.27% | -515 -253 -103.57% | -151 -473 68.06% | -190 -283 33.05% | -182 |
|
EPS EUR | Released Forecast Spread | -3,26 -3,11 -4.88% | 2,97 0,61 384.97% | -15,4 -7,94 -94.05% | -4,42 -13,4 66.95% | -5,53 -8,13 31.97% | -4,23 |
| Announcement Date | 18/03/20 | 15/03/21 | 16/03/22 | 15/03/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million EUR | Released Forecast Spread | 270 263 2.65% | 52,9 44,0 20.19% | 41,5 46,6 -10.94% | 59,4 47,4 25.32% | 95,8 64,0 49.6% | 81,6 51,2 59.36% | 62,3 42,3 47.45% | 53,2 54,8 -2.86% | 63,8 57,5 10.99% | 59,0 59,4 -0.64% | 55,4 | 49,9 | 51,5 | 54,6 |
|
EBITDA Million EUR | Released Forecast Spread | -79,3 -102 22.36% | |||||||||||||
|
EBIT Million EUR | Released Forecast Spread | 163 171 -4.45% | -94,3 -99,4 5.14% | -68,0 -16,0 -325% | -55,1 -60,9 9.53% | -29,3 -57,8 49.34% | -68,4 -133 48.63% | -69,5 -77,5 10.35% | -50,5 -70,8 28.65% | -51,0 -65,0 21.6% | -81,4 -82,3 1.09% | -35,4 | -41,0 | -39,7 | -37,9 |
|
Earnings before Tax (EBT) Million EUR | Released Forecast Spread | -123 -18,0 -581.67% | -123 -58,9 -108.83% | -44,4 | -74,0 -77,0 3.9% | -119 -70,0 -70.14% | 46,7 -40,1 216.56% | -36,5 | -36,5 | -46,5 | -50,5 | ||||
|
Net income Million EUR | Released Forecast Spread | 180 153 17.49% | -123 -14,0 -776.43% | -235 -78,6 -198.98% | -123 -49,0 -150.82% | 329 194 69.82% | -44,4 -122 63.61% | -74,0 -75,9 2.51% | -120 -62,1 -92.69% | 48,3 -76,1 163.46% | -46,4 | -49,1 | -57,0 | -61,2 | |
|
EPS EUR | Released Forecast Spread | 5,54 4,78 15.9% | -11,2 -4,94 -125.91% | -3,59 -0,43 -734.88% | -6,88 -2,55 -169.8% | -3,60 -2,05 -75.61% | 9,65 0,37 2484.84% | -1,30 -2,76 52.81% | -2,16 -2,35 8.09% | -3,50 -1,86 -88.34% | 1,22 -2,42 150.31% | -0,31 | -1,25 | -1,05 | -1,39 |
| Announcement Date | 05/08/20 | 16/03/22 | 04/05/22 | 03/08/22 | 16/11/22 | 15/03/23 | 03/05/23 | 09/08/23 | 15/11/23 | 13/03/24 | - | - | - | - |
More events
Past sector events for MorphoSys AG
| 2024-04-17 | HINOVA PHARMACEUTICALS INC.: Q4 2023 Earnings Release |
| 2024-04-17 02:07 am | TELIX PHARMACEUTICALS LIMITED: March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-10 04:10 pm | PHARVARIS N.V.: Q4 2023 Earnings Release |
| 2024-04-10 01:22 am | POLARIS GROUP: March 2024 Sales and Revenue Release |
| 2024-04-02 02:30 am | ABIVAX: Q4 2023 Earnings Release |
| 2024-04-01 09:00 am | BIOMEA FUSION, INC.: Q4 2023 Earnings Release |
| 2024-03-28 10:42 pm | ALPHAMAB ONCOLOGY: Q4 2023 Earnings Release |
| 2024-03-28 04:28 pm | CENTESSA PHARMACEUTICALS PLC: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ARRIVENT BIOPHARMA, INC.: Q4 2023 Earnings Release |
| 2024-03-28 07:10 am | HANGZHOU TIGERMED CONSULTING CO., LTD: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- MOR Stock
- Calendar MorphoSys AG
